Pipeline

About AMX0035

AMX0035 is our first-in-class investigational product — an oral fixed-dose co-formulation of two active compounds, sodium phenylbutyrate (PB) and taurursodiol (TURSO) — optimized to address both the toxic, unfolded proteins in the endoplasmic reticulum and the energy crisis in the mitochondria that occur in neurodegenerative diseases. We are currently exploring the potential of AMX0035 as a treatment option for ALS, Alzheimer’s disease and Wolfram syndrome. Our aim is to expand upon this innovation to address other neurodegenerative diseases.

Clinical Trials

CENTAUR TRIAL: OUR PATH TO PROGRESS

CENTAUR was a 24-week, randomized, double-blind, placebo-controlled Phase II trial that evaluated AMX0035 in people with ALS. The primary objectives of the study were to assess the safety and tolerability of AMX0035 as well as the impact of AMX0035 on disease progression, as measured by the Revised ALS Functional Rating Scale (ALSFRS-R). Additional measures that are critical to people with ALS, including muscle strength and slow vital capacity, were also assessed in CENTAUR.

The CENTAUR study enrolled participants between 18 and 80 years old with definite ALS — and within 18 months of symptom onset — and allowed edaravone or riluzole use.

Conducted by investigators at 25 top ALS medical centers throughout the Northeast ALS (NEALS) consortium, the CENTAUR trial completed in late 2019. AMX0035 demonstrated statistically significant functional benefits for people with ALS, based on the ALS Functional Rating Scale (ALSFRS-R). Of the participants who completed CENTAUR, 92% elected to enroll in an open-label extension study. In the CENTAUR trial, participants experienced similar rates of adverse events in the AMX0035 and placebo groups.

The importance of moving forward as efficiently as possible is not something we take lightly, as people living with ALS don’t have time to wait. Amylyx continues to discuss AMX0035 with health authorities around the world to determine the most appropriate path forward in each territory and will continue to keep the global ALS community updated. Read the latest news here.

PEGASUS TRIAL: A NEW WAY FORWARD

Recognizing that AMX0035 has potential with other neurodegenerative diseases, Amylyx initiated the PEGASUS trial in participants with late mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease in 2018. The Phase II PEGASUS trial is evaluating the safety, tolerability and biological activity of AMX0035 in 96 participants over 24 weeks of treatment. PEGASUS was supported by the Alzheimer’s Combination Therapy Opportunities (ACTO) program, a joint research funding initiative supported by the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation, and Cure Alzheimer’s Fund. Top-line results of the PEGASUS trial are expected to be available in 2021.

The primary purpose of the trial is to investigate the safety and tolerability of AMX0035 in participants with Alzheimer’s disease, however, the inclusion of trial endpoints such as cognitive function, brain imaging and spinal fluid biomarkers will provide an informative dataset that will allow for evaluation and correlation of imaging-based markers, neurobiological changes, functional measures, and cognitive outcomes in Alzheimer’s disease.

Latest News

Amylyx Pharmaceuticals Announces Plan to Submit New Drug Application (NDA) for AMX0035 for the Treatment of ALS in the Coming MonthsSeptember 15, 2021

Amylyx Pharmaceuticals, Inc. today announced its intention to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for AMX0035 (sodium phenylbutyrate (PB) and taurursodiol (TURSO)) for the treatment of amyotrophic lateral sclerosis (ALS). The decision by the company to submit the application in the coming months follows recent discussions with the FDA, including a pre-NDA meeting held on July 15, 2021. “We are thrilled to move toward the U.S. submission of an NDA for AMX0035 and look forward to continuing to work with the FDA,” said Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx. “For those living with ALS, time is the most important resource, and we remain focused on advancing AMX0035 through the clinical development process as efficiently as possible,” added Justin Klee, Co-CEO, Director and Co-Founder of Amylyx. “We’re endlessly grateful for all of the support and efforts of ALS Finding a Cure, the ALS Association, I AM ALS, the Healey &

Read More
Logo for Pegasus
Pegasus Alzheimer’s Trial

PEGASUS is a 3:2 randomized, double-blind, multi-center, placebo-controlled trial evaluating the safety, tolerability and activity of AMX0035 in patients with late mild cognitive impairment or early dementia due to Alzheimer’s disease over 24 weeks.

More Information
Image of Amylyx employees
Careers

Amylyx was built on the foundation of audacious curiosity, relentless drive, and meaningful relationships. If that sounds like you, we’d love to talk.

Open Positions

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.